YOLFTbeta
Q32 Bio Inc

Q32 Bio Inc

QTTB · NASDAQ · Healthcare / Biotechnology

8.71USD-0.11 (-1.25%)

Price History

Full chart

Market Stats

Previous Close8.82
Open8.83
Day Range8.45 – 8.95
52-Week Range1.91 – 23.57
Volume243.79K
Market Cap274.77M
P/E (TTM)2.79
Forward P/E0.00
EPS3.31
Dividend Yield0.00%
Beta-0.38
50-Day Avg13.86
200-Day Avg8.62

About

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb " CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Jodie Pope Morrison
  • Employees22
  • Headquarters830 Winter Street, Waltham, MA, United States, 02451, USA
  • Websitehttps://www.q32bio.com

Leadership

  • Ms. Jodie Pope MorrisonCEO & Director · b. 1976
  • Mr. Lee H. Kalowski M.B.A.CFO & President · b. 1981
  • Dr. Shelia M. Violette Ph.D.Co-founder, Chief Scientific Officer & President of Research · b. 1961
  • Mr. David Appugliese J.D.Senior VP & Head of People
  • Ms. Maria Marzilli M.P.H.Chief Business Officer

Financials

Income Statement

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--5.32M1.67M2.70M33.97M6.65M-6.65M053.74M
Growth (%)----68.70%+62.18%+1157.25%-80.42%-200.00%+100.00%-
Cost of Revenue239.80K684.21K---9.54M2.60M499.00K487.00K391.00K
Gross Profit-239.80K-684.21K5.32M1.67M2.70M24.43M6.65M-6.65M-487.00K53.74M
Gross Margin--100.00%100.00%100.00%71.91%100.00%100.00%-100.00%
Operating Expense9.76M28.97M65.25M111.61M132.97M61.12M45.88M41.60M65.61M36.84M
Operating Income-10.00M-29.66M-59.93M-109.94M-130.26M-36.69M-39.23M-48.26M-66.10M16.90M
Operating Margin---1126.01%-6599.22%-4820.98%-108.01%-589.76%725.53%-31.45%
EBITDA-7.81M-29.31M-58.64M-97.60M-121.36M-36.65M-38.85M-47.76M-44.50M31.31M
EBITDA Margin---1101.79%-5858.22%-4491.45%-107.87%-584.20%718.03%-58.27%
Net Income-8.05M-29.99M-55.58M-103.92M-128.69M-37.56M-42.81M-53.74M-47.73M29.82M
Net Income Margin---1044.29%-6237.45%-4762.92%-110.58%-643.65%808.04%-55.49%
R&D5.69M21.38M47.95M89.40M100.39M29.93M35.81M31.73M48.14M19.16M
R&D as % of Total Revenue--900.94%5366.03%3715.47%88.10%538.48%-477.06%-35.65%
Interest Expense-------1.50M1.10M1.10M
Interest Expense % of Total Revenue--------22.55%-2.05%

Balance Sheet

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets14.22M137.53M259.09M310.57M263.74M211.72M229.53M47.06M92.33M61.78M
Total Liabilities6.72M39.22M62.74M52.06M67.74M42.07M51.54M229.98M86.66M19.76M
Total Equity7.50M98.31M196.35M258.51M196.00M169.65M177.98M-182.92M5.67M42.01M
Cash11.39M51.57M38.22M53.77M217.43M108.38M33.99M25.62M77.97M48.30M
Total Debt----15.44M23.93M29.95M50.84M18.90M15.34M
Net Debt-11.39M-51.57M-38.22M-53.77M-201.99M-84.45M-4.04M25.22M-59.06M-32.95M

Cash Flow

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-8.48M6.48M-42.56M-91.36M-94.33M-109.75M-10.96M-18.68M-67.72M-33.54M
Investing Cash Flow-2.27M-81.53M-121.79M-51.80M204.90M-50.79M-2.47M-5.00K19.93M7.00M
Financing Cash Flow378.31K115.23M150.99M158.21M53.09M52.17M30.07M406.00K95.14M-3.13M
Capital Expenditure1.99M1.96M24.94M21.83M3.73M2.40M2.48M5.00K75.00K2.00K
Free Cash Flow-10.47M4.52M-67.50M-113.19M-98.06M-112.15M-13.44M-18.68M-67.79M-33.54M
FCF to OCF123.45%69.78%158.59%123.90%103.96%102.18%122.68%100.03%100.11%100.00%

Earnings

Report DateFeb 28, 2018May 14, 2018Aug 13, 2018Nov 13, 2018Mar 12, 2019May 13, 2019Aug 8, 2019Nov 12, 2019Mar 12, 2020May 7, 2020Aug 10, 2020Nov 9, 2020Mar 11, 2021May 6, 2021Aug 12, 2021Nov 15, 2021Mar 23, 2022May 16, 2022Aug 15, 2022Nov 10, 2022Mar 9, 2023May 11, 2023Aug 14, 2023Nov 14, 2023Mar 13, 2024May 9, 2024Aug 8, 2024Nov 7, 2024Mar 11, 2025May 8, 2025Aug 6, 2025Nov 13, 2025Mar 10, 2026May 5, 2026Aug 5, 2026Nov 12, 2026
EPS Estimate0.00-3.78-0.33-0.37-0.44-0.54-0.55-0.60-0.68-0.69-0.74-0.81-0.66-0.61-0.57-0.59-0.57-0.49-0.54-0.46-0.49-0.52-0.50-0.43-0.30-1.41-1.04-1.45-1.53-1.23-0.98-1.19-0.86-0.68-0.53-0.36
EPS Actual-0.32-0.15-0.16-7.20-9.18-11.52-10.98-12.06-9.90-14.04-14.04-11.16-11.16-0.36-9.72-9.72-10.6228.62-9.18-10.62-10.80-0.50-0.61-0.57-0.281.03-1.42-1.46-1.16-0.90-0.78-0.604.58-0.54-0.44-
Surprise-96.03%51.52%-1845.95%-1986.36%-2033.33%-1896.36%-1910.00%-1355.88%-1934.78%-1797.30%-1279.82%-1593.99%41.35%-1590.43%-1555.88%-1748.89%5909.99%-1607.59%-2226.91%-2094.23%3.85%-22.00%-32.56%6.67%173.05%-36.54%-0.69%24.18%26.83%20.41%49.58%632.56%20.59%16.98%-
Timing------------------------Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-market-

Key Statistics & Ratios

Market Cap274.77M
Enterprise Value183.18M
Trailing P/E2.79
Forward P/E0.00
Price / Sales5.11
Price / Book2.68
EPS3.31
Book Value4.46
Revenue (TTM)53.74M
Gross Profit (TTM)39.39M
EBITDA21.82M
Profit Margin62.87%
Operating Margin39.94%
Return on Equity72.14%
Return on Assets14.74%
Shares Outstanding29.77M
Shares Float14.44M
Beta-0.38
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 3 analystsTarget 39.60
  • Strong Buy
    1
  • Hold
    2

Ownership Breakdown

Institutions
79.43%
Insiders
2.77%
Retail / Other
17.80%

Top Institutional Holders

  • Atlas Venture Life Science Advisors, LLC
    2.72M16.02%
  • Orbimed Advisors LLC
    2.25M13.29%
  • Opaleye Management Inc
    931.00K5.49%
  • Logos Global Management LP
    800.00K4.72%
  • Vanguard Capital Management, LLC
    306.40K1.81%
  • American Century Companies Inc
    272.75K1.61%
  • Mackenzie Investments
    246.30K1.45%
  • Sanofi
    244.08K1.44%
  • Renaissance Technologies Corp
    206.91K1.22%
  • Acadian Asset Management LLC
    172.59K1.02%
  • MONIMUS CAPITAL MANAGEMENT, LP
    132.04K0.78%
  • Citadel Advisors Llc
    120.66K0.71%
  • Geode Capital Management, LLC
    118.15K0.70%
  • Pfizer Inc
    101.62K0.60%
  • BlackRock Inc
    86.15K0.51%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    755.25K2.54%
  • Avantis US Small Cap Value ETF
    510.36K1.71%
  • JPMorgan Small Cap Growth A
    508.06K1.71%
  • MEDICAL BioHealth EUR Acc
    181.02K0.61%
  • JPMorgan Small Cap Blend A
    161.06K0.54%

Stock Splits

  • Mar 26, 20241:18